FDA approves first oral Wegovy GLP‑1 pill for obesity
The FDA has approved Wegovy’s daily oral semaglutide pill—the first prescription oral GLP‑1 specifically for obesity—after trials showing roughly 13–17% average body‑weight loss versus about 2–3% for placebo, nearly matching the injectable’s results. Manufactured in North Carolina and expected to roll out in the coming weeks/early January with a reported starter price around $149/month, the tablet must be taken in the morning on an empty stomach with a 30‑minute wait before eating, and Novo Nordisk says pills should be easier to produce and broaden access, though common GLP‑1 side effects (nausea, diarrhea) remain.
📌 Key Facts
- The FDA approved a daily oral version of Wegovy (25 mg semaglutide), the first prescription oral GLP‑1 medication specifically authorized to treat obesity in the U.S.
- In clinical trials, participants taking the oral Wegovy pill lost substantially more weight than placebo: reported average total body‑weight reductions ranged from about 13.6% to roughly 17% over roughly 64 weeks–15 months, versus about 2–3% in placebo groups; NPR noted these results nearly match injectable Wegovy’s ~15% average loss.
- The pill must be taken in the morning on an empty stomach with a sip of water and patients must wait 30 minutes before eating or drinking, due to a protective absorption enhancer in the formulation.
- Common GLP‑1 side effects were reported (nausea, diarrhea); other competing drugs in development include Lilly’s orforglipron — which produced about 11.2% weight loss at its highest dose and has no dosing restrictions and is under priority FDA review — and Zepbound, which targets GLP‑1 and GIP and has shown higher average loss (~21%).
- Novo Nordisk says the active ingredient for the oral Wegovy pill will be manufactured in North Carolina and that pills are expected to be easier to produce than injectables, reducing the risk of shortages; company executives say they are 'confident and ready to meet demand.'
- The company plans a near‑term rollout: outlets report the pill should be available in a matter of weeks to early January, with Axios reporting a starting dose price of about $149 per month.
- Observers expect oral GLP‑1s to broaden access and reduce costs for patients: roughly 1 in 8 Americans have used injectable GLP‑1s but many struggle to afford the shots, and the pill format could address some barriers.
- Coverage included patient perspectives and expert commentary: NPR featured a trial participant (Dr. Chris Mertens) who said he lost about 40 pounds on the pill and experienced markedly reduced appetite; CBS aired on‑air medical context from Dr. Jon LaPook (clip did not specify details).
📊 Relevant Data
In 2025, adult obesity rates in the US were highest among Black adults at 49.9%, followed by Latino adults at 45.6%, compared to the overall rate of about 40%, with US population demographics approximately 13% Black and 19% Hispanic.
State of Obesity Report 2025 : Better Policies for a Healthier America — Trust for America's Health
Obesity prevalence was highest in non-Hispanic American Indian/Alaska Native adults at 44.0%, followed by non-Hispanic Black adults at 42.7%, based on 2021-2022 data, with population percentages of about 1% for American Indian/Alaska Native and 13% for Black.
Racial and Ethnic Disparities in Obesity and Contributing Behavioral, Social, and Psychological Factors: A Scoping Review — ScienceDirect
Socioeconomic status, including education and household income, contributes to higher obesity rates, with disparities observed across racial groups where lower socioeconomic status correlates with increased obesity prevalence.
Rising Obesity Rates in America: A Public Health Crisis — Obesity Medicine Association
Adults in rural areas have higher obesity rates than those in urban areas, with a 0.3 percentage point decline in urban rates from 2022-2023 to 2023-2024, and certain racial groups like Black and Latino adults are more likely to live in areas with higher obesity prevalence.
U.S. Obesity Rate Changes Differ for Rural and Urban Areas, as Well as Across Regions — USDA Economic Research Service
📰 Sources (4)
- Confirms that the pill version of Wegovy is characterized as the first prescription oral weight‑loss medication of its kind.
- States that the new Wegovy pills are expected to be available to patients in a matter of weeks, narrowing the expected rollout window.
- Includes on‑air expert context from CBS chief medical correspondent Dr. Jon LaPook, though the clip text does not detail his specific medical commentary.
- Confirms FDA approval of a daily oral Wegovy pill (25 mg semaglutide) as the first oral GLP‑1 medication specifically approved to treat obesity in the U.S.
- Reports that oral Wegovy produced 13.6% average total body weight loss over about 15 months in trials, versus 2.2% for placebo, nearly matching injectable Wegovy’s ~15% result.
- Notes that about 1 in 8 Americans have used injectable GLP‑1 drugs, but many struggle to afford the shots, and experts expect pills to broaden access and reduce costs.
- Details dosing constraints: the Wegovy pill must be taken in the morning with a sip of water on an empty stomach, with a 30‑minute wait before eating or drinking, due to a protective absorption enhancer.
- Contrasts Lilly’s competing oral GLP‑1, orforglipron, which has no dosing restrictions, produced 11.2% average weight loss at the highest dose, and is under priority FDA review with a decision expected by spring.
- Reiterates common GLP‑1 side effects (nausea, diarrhea) and notes Zepbound’s higher average weight loss (~21%) by targeting both GLP‑1 and GIP.
- Includes patient anecdote from a trial participant, Dr. Chris Mertens, who lost about 40 pounds on the Wegovy pill and described markedly reduced appetite and food preoccupation.
- Axios specifies that the FDA approval covers a daily 1.5 mg oral version of Wegovy with a starting dose priced at $149 per month, available in early January.
- Novo Nordisk reports that in a 64‑week clinical trial, participants on the daily pill, combined with reduced calorie intake and increased exercise, lost about 17% of body weight on average compared with 3% in the placebo group.
- Novo Nordisk says the active ingredient for the oral Wegovy pill will be manufactured in North Carolina.
- Company executives emphasize that pills are expected to be easier to manufacture than injectables, reducing shortage risk, and state they are 'confident and ready to meet demand' for the Wegovy pill.